ERT Named Finalist for 2018 Scrip Award

Advanced technology imaging solution recognized for disruptive improvements in clinical trial data

PHILADELPHIA – October 2, 2018ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced its advanced technology imaging solution has been named a finalist in the 2018 Scrip Awards, Best Technological Development in Clinical Trials – Tech Sponsor-focused category.

Mike Ward, Global Director of Content, Scrip noted, “The 2018 Scrip Awards provide the biopharma industry with an opportunity to acknowledge its highest achievers across the entire value chain, and to recognize the organizations that are using the most sophisticated platforms to catalyze and optimize clinical trial data. We’re pleased to recognize and shortlist ERT for its advancements in improving imaging data quality to support safety and efficacy endpoints during clinical trials.”

ERT’s advanced technology imaging solution is purpose-built for clinical trials, enabling sponsors to improve imaging data consistency, objectivity and transparency and to run more efficient studies. The solution enables the analysis, management, reporting and submission of high-quality imaging data that supports clinical trial objectives and meets regulators’ increasing requests for imaging endpoints in clinical development.

“We’re pleased to be among this distinguished group of finalists being recognized for their dedication to advancing drug development,” said Tim Kulbago, Vice President of Imaging, ERT. “The current state of imaging in clinical research is dated and ripe for innovative disruption; the industry is in acute need of a comprehensive solution that provides the best technology and science to achieve higher quality data. We’re honored that ERT’s advanced technology imaging solution is being recognized for meeting these needs.”

For more information on ERT’s imaging solution for clinical research, visit ert.com/imaging.

###

ERTについて
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. ERTは50年近い臨床経験および治療経験を有しており、実際に機能することの知識と今後の出来事の予測を調和させて、基準を低下させることなく適応することができます。

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. ERTは2017年に、FDAに承認された医薬品の60%超をサポートしました。製薬企業、バイオ医薬品企業、およびCROは、これまでに300万人以上の患者を対象とした13,000件を超える臨床試験でERTのソリューションを活用してきました。ERTは、臨床試験のリスクが問題になる前にこのリスクを明確にして、顧客が臨床治療を迅速に患者に適用することを可能にします。しかも自信をもって。

詳細な情報については、ert.comをご参照ください。またはLinkedInTwitterで当社をフォローしてください。

シェアする